By disrupting CXCL12–CXCR4 binding, CXCR4 antagonism may, in principle, interfere with malignant T-cell trafficking and retention programs relevant to CTCL. Here, CXCR4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.